Want to join the conversation?
$VRTX 2Q15 Q&A: Geoffrey of Barclays clarified if Vertex was rethinking some of the endpoints overall for development beyond FEV1, and Jeffrey Leiden said the company is eager to explore additional endpoints to FEV1, particularly for younger populations where it is more difficult to consistently blow a good FEV1 if one is 2/3-years-old.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)